Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01791920
Other study ID # HG-11-01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 2011
Est. completion date March 2012

Study information

Verified date February 2013
Source Hugel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the safety and efficacy of Botulax® with Botox® in the improvement of moderate to severe glabellar lines.


Recruitment information / eligibility

Status Completed
Enrollment 262
Est. completion date March 2012
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Men and women aged between 18 and 65 - Patients attaining grade 2 or 3 in the investigator's rating of glabellar lines severity at maximum frown - Patients who voluntarily sign the informed consent - Patients who can comply with the study procedures and visit schedule Exclusion Criteria: - Subjects who had facial plastic surgery (tissue augmentation, brow lift, and dermal resurfacing)treatment within 6 months. Those who had peeling or laser therapy - Subjects with skin disorders, scar or infection around glabellar region - Subjects who are taking Aspirin, NSAIDS or anti-coagulant - Subjects with facial palsy or eyelid ptosis - Subjects who diagnosed as neuromuscular junction disorder (e.g., myasthenia gravis, Lambert-Eaton Syndrome) - Subjects with history of drug intoxication, alcohol abuse and/or depressive disorder - Subjects with severe internal diseases (cardiovascular, respiratory, renal disease, liver disorder) - Subjects who have previously been treated with botulinum toxin within 3 months (Botulinum toxin type A: 3months, type B: 4 months) - Subject who have administered following drugs within the previous 4 months: Spectinomycin Hydrochloride, Aminoglycoside antibiotics, polypeptide antibiotics, tetracycline antibiotics, lincomycin antibiotics, muscle relaxants, anti-cholinergic agents, benzodiazepine and similar drugs, benzamide drugs, Tubocurarine-type muscle relaxants - Subjects who have possibility to take the drugs listed above - Subjects who have a plan to receive facial cosmetic procedures including dermal filler, chemical peeling and dermabrasion during study period - Subjects who have glabellar lines that are unable to be improved with any physical method - Subjects who have history of hypersensitivity to Botulinum toxin and other agents - Subjects who are pregnant or breast-feeding - Subjects who have a plan to be pregnant in 3months, or who are not doing contraceptive - Subjects who participated in other studies within 30 days or were not passed over 5 times of half life for investigational product - Subjects who are having trouble with acute disease - Subjects who have taken any treatment that can affect to glabellar lines and/or any lines around forehead within the previous 6 months - Subjects who are unable to communicate or follow the instructions - Subjects who are not eligible for this study based on investigator's judgement

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum toxin type A(Botulax®)
Single administration, Day 0, 20 units
Botulinum toxin type A(Botox®)
Single administration, Day 0, 20units

Locations

Country Name City State
Korea, Republic of Chung-Ang University Hopspital Seoul Dongjak-gu
Korea, Republic of Eulji General Hospital Seoul Nowon-Gu
Korea, Republic of Korea University Anam Hospital Seoul Seongbuk-Gu
Korea, Republic of National Medical Center Seoul Jung-Gu
Korea, Republic of Seoul National University Hospital Seoul Jongno-Gu
Korea, Republic of The catholic university of Korea, Seoul ST. Mary's Hospital Seoul Seocho-Gu

Sponsors (1)

Lead Sponsor Collaborator
Hugel

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Responder rate of improvement in glabellar lines with Physician's rating of line severity Improvement rate of glabellar lines at maximum frown with Physician's rating of lines severity at 4weeks post injection. at 4 weeks post-injection
Secondary Safety evaluation in experimental drug treatment group 4, 8, 12, 16 weeks post-injection
Secondary Responder rate of improvement in glabellar lines with Physician's rating of line severity Improvement rate of glabellar lines at maximum frown with Physician's rating of lines severity at 8, 12, 16weeks post injection. 8, 12, 16 weeks post-injection
Secondary Responder rate of improvement in glabellar lines at rest with investigator's live assessment of severity Improvement rate of glabellar lines at rest with investigator's live assessment of severity at 4, 8, 12, 16weeks post injection 4, 8, 12, 16 weeks post-injection
Secondary Responder rate of improvement in glabellar lines at maximum frown with investigator's photo assessment Improvement rate of glabellar lines at maximum frown with investigator's photo assessment at 4, 8, 12, 16weeks post injection 4, 8, 12, 16 weeks post-injection
Secondary Responder rate of improvement in glabellar lines at rest with investigator's photo assessment Improvement rate of glabellar lines at rest with investigator's photo assessment at 4, 8, 12, 16weeks post injection 4, 8, 12, 16 weeks post inejection
Secondary Responder rate of improvement in glabellar lines with Subject's improvement assessment Improvement rate of glabellar lines with Subject's improvement assessment at 4, 8, 12, 16weeks post injection 4, 8, 12, 16 weeks post-injections
Secondary Subject's satisfaction rate Subject's satisfaction rate of improvement in glabellar lines at 4, 8, 12, 16 weeks post injection 4, 8, 12, 16 weeks post-injection
See also
  Status Clinical Trial Phase
Completed NCT04276753 - A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects N/A
Completed NCT06125912 - A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging N/A
Completed NCT02580370 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines Phase 3
Recruiting NCT01583478 - Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Phase 4
Completed NCT02003833 - Poly-L-lactic Acid for Skin Quality Phase 4
Completed NCT01447342 - A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines Phase 2/Phase 3
Completed NCT00986570 - Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face Phase 3
Completed NCT00974480 - Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging N/A
Completed NCT00272610 - Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin Phase 2
Recruiting NCT03730649 - Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure Early Phase 1
Completed NCT03312543 - Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles N/A
Active, not recruiting NCT05349799 - TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines N/A
Completed NCT03677258 - Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy N/A
Withdrawn NCT05854628 - The Role of Red Flavonoid in Photoaging N/A
Completed NCT01981980 - Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation N/A
Not yet recruiting NCT00767156 - Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging N/A
Recruiting NCT05813054 - Clinical Study to Evaluate the Anti-aging Efficacy of Dermial® N/A
Not yet recruiting NCT04485091 - TCA Peel and Photobiomodulation for Hand Rejuvenation Phase 2
Completed NCT05457491 - Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) Phase 1
Completed NCT01237977 - Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines Phase 3